- Member Benefits
- Manage your personalised Watchlist.
- Set up an online Virtual Portfolio.
- Participate in Share Chat.
- See more trades and director dealings.
- Play the Fantasy Share Trading Game.
Share:
HomeShare PricesStock PickerFinancial DiaryUK IndicesUK Industry SectorsCompany LookupShare RisersShare FallersBroker RatingsFinance GlossarySMS ServicesShare ChatFinance NewsBlogsLive PricesShares BookshopFinance ToolsMembers
Latest Share Chat
Gw Pharmaceuticals Share News (GWP)
Share News for Gw Pharmaceuticals (GWP)
| Share Price: 51.00 | Bid: 48.00 | Ask: 50.00 | Change: 0.00 (0.00%) |  | ||||||
| ||||||||||
UPDATE 1-GW's cannabis-based drug shows long-term efficacy
Mon, 8th Sep 2008 07:53
LONDON, Sept 8 (Reuters) - GW Pharmaceuticals Plc announced on Monday that a study of its cann
It is the first time that the long-term effectiveness of the drug had been demonstrated in a so-called placebo-controlled study, where it is tested against a dummy drug.
The news is also significant for the company because it bolsters hopes that it might gain approval for the drug as a treatment for spasticity associated with multiple sclerosis, because the trial is very similar to a late-stage trial that has been running at the request of regulators.
Stephen Wright, GW's R&D Director, said in a statement: 'It is encouraging to note that if the difference between Sativex and placebo achieved in the results today are replicated in the ongoing Phase III MS spasticity study, this Phase III study will meet its objectives.'
This study is due to report results in the first quarter of 2009 with a regulatory submission planned for the first half of 2009.
tf.TFN-Europe_newsdesk@thomson.com
ak
COPYRIGHT
Copyright Thomson Financial News Limited 2008. All rights reserved.
The copying, republication or redistribution of Thomson Financial News Content, including by framing or similar means, is expressly prohibited without the prior written consent of Thomson Financial News.
LONDON, Sept 8 (Reuters) - GW Pharmaceuticals Plc announced on Monday that a study of its cann
abis-based pain killer Sativex has shown long-term efficacy in the treatment of neuropathic pain due to multiple sclerosis.
It is the first time that the long-term effectiveness of the drug had been demonstrated in a so-called placebo-controlled study, where it is tested against a dummy drug.
The news is also significant for the company because it bolsters hopes that it might gain approval for the drug as a treatment for spasticity associated with multiple sclerosis, because the trial is very similar to a late-stage trial that has been running at the request of regulators.
Stephen Wright, GW's R&D Director, said in a statement: 'It is encouraging to note that if the difference between Sativex and placebo achieved in the results today are replicated in the ongoing Phase III MS spasticity study, this Phase III study will meet its objectives.'
This study is due to report results in the first quarter of 2009 with a regulatory submission planned for the first half of 2009.
tf.TFN-Europe_newsdesk@thomson.com
ak
COPYRIGHT
Copyright Thomson Financial News Limited 2008. All rights reserved.
The copying, republication or redistribution of Thomson Financial News Content, including by framing or similar means, is expressly prohibited without the prior written consent of Thomson Financial News.
STOCKS NEWS EUROPE-UK small caps advance 0.2 percent
UK small caps rise 0.2 percent, while the blue chips climb 0.3 percent, and the midcaps are 0.1 percent higher.GW Pharmaceuticals adds 7.5 percent aft[7 May '13]
UPDATE 1-GW, Almirall may pull cannabis drug in German price row
* Germany refuses to pay "acceptable" price for Sativex* Almirall to challenge price decision, may withdraw supply* GW Pharmaceuticals aims to list sh[19 Mar '13]
Journal questions use of cannabis spray drug for MS
LONDON, Dec 13 (Reuters) - There is little evidence to back the use of a cannabis extract spray made by GW Pharmaceuticals for spasticity in pa[12 Dec '12]
BRIEF-GW Pharma Sativex study shows MS spasticity benefits
LONDON, Oct 12 (Reuters) - GW Pharmaceuticals PLC: * Positive German sativex data presented at ectrims * confirms clinically relevant[12 Oct '12]
BRIEF-GW Pharma appoints Chris Tovey COO
LONDON, Oct 1 (Reuters) - GW Pharmaceuticals PLC: * Appointment of chief operating officer ((London Equities Newsroom; +44 20 7542 77[1 Oct '12]
Drug firm GW to test cannabis chemical in epilepsy
LONDON, Sept 13 (Reuters) - A British drug company aims to test a compound found in cannabis as a treatment for epilepsy, following a promising[13 Sep '12]
BRIEF-GW Pharma's Sativex gets German boost
LONDON, June 22 (Reuters) - GW Pharmaceuticals PLC: * German G-BA establishes positive additional benefit of Sativex in Multiple Sclerosis[22 Jun '12]
BRIEF-GW Pharma's Sativex set for approval in 10 countries
LONDON, May 8 (Reuters) - GW Pharmaceuticals PLC: * Pharma - sativex mutual recognition procedure closes with recommendation for ap[8 May '12]
